Logo image of BDX

BECTON DICKINSON AND CO (BDX) Stock Price, Forecast & Analysis

USA - New York Stock Exchange - NYSE:BDX - US0758871091 - Common Stock

191.82 USD
-2.2 (-1.13%)
Last: 12/1/2025, 8:04:00 PM
191.82 USD
0 (0%)
After Hours: 12/1/2025, 8:04:00 PM

BDX Key Statistics, Chart & Performance

Key Statistics
Market Cap54.98B
Revenue(TTM)21.84B
Net Income(TTM)1.68B
Shares286.63M
Float284.95M
52 Week High251.99
52 Week Low162.29
Yearly Dividend4.15
Dividend Yield2.17%
EPS(TTM)14.42
PE13.3
Fwd PE12.8
Earnings (Next)02-03 2026-02-03
IPO1963-09-25
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment


BDX short term performance overview.The bars show the price performance of BDX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 2 4 6 8 10

BDX long term performance overview.The bars show the price performance of BDX in the last 1, 2 and 3 years. 1 year 2 years 3 years -5 -10 -15 -20

The current stock price of BDX is 191.82 USD. In the past month the price increased by 7.34%. In the past year, price decreased by -12.82%.

BECTON DICKINSON AND CO / BDX Daily stock chart

BDX Latest News, Press Relases and Analysis

BDX Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 25.65 222.59B
ISRG INTUITIVE SURGICAL INC 65.9 201.13B
BSX BOSTON SCIENTIFIC CORP 34.24 149.74B
SYK STRYKER CORP 28.27 142.38B
IDXX IDEXX LABORATORIES INC 57.81 58.21B
EW EDWARDS LIFESCIENCES CORP 33.18 49.48B
RMD RESMED INC 25.09 36.26B
GEHC GE HEALTHCARE TECHNOLOGY 17.26 36.10B
DXCM DEXCOM INC 34.15 24.77B
PODD INSULET CORP 68.02 21.87B
ZBH ZIMMER BIOMET HOLDINGS INC 11.71 18.78B
HOLX HOLOGIC INC 17.53 16.68B

About BDX

Company Profile

BDX logo image Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. The company is headquartered in Franklin Lakes, New Jersey and currently employs 74,000 full-time employees. The firm is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.

Company Info

BECTON DICKINSON AND CO

One Becton Drive

Franklin Lakes NEW JERSEY 07417 US

CEO: Thomas E. Polen

Employees: 74000

BDX Company Website

BDX Investor Relations

Phone: 12018476800

BECTON DICKINSON AND CO / BDX FAQ

Can you describe the business of BECTON DICKINSON AND CO?

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. The company is headquartered in Franklin Lakes, New Jersey and currently employs 74,000 full-time employees. The firm is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.


Can you provide the latest stock price for BECTON DICKINSON AND CO?

The current stock price of BDX is 191.82 USD. The price decreased by -1.13% in the last trading session.


Does BECTON DICKINSON AND CO pay dividends?

BECTON DICKINSON AND CO (BDX) has a dividend yield of 2.17%. The yearly dividend amount is currently 4.15.


What is the ChartMill rating of BECTON DICKINSON AND CO stock?

BDX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


When is the next dividend date for BECTON DICKINSON AND CO (BDX)?

The next ex-dividend date for BECTON DICKINSON AND CO (BDX) is December 8, 2025.


Is BECTON DICKINSON AND CO (BDX) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BDX.


What is the employee count for BDX stock?

BECTON DICKINSON AND CO (BDX) currently has 74000 employees.


BDX Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to BDX. When comparing the yearly performance of all stocks, BDX is a bad performer in the overall market: 70.27% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BDX Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to BDX. BDX scores excellent on profitability, but there are concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BDX Financial Highlights

Over the last trailing twelve months BDX reported a non-GAAP Earnings per Share(EPS) of 14.42. The EPS increased by 9.57% compared to the year before.


Industry RankSector Rank
PM (TTM) 7.68%
ROA 3.03%
ROE 6.61%
Debt/Equity 0.69
Chartmill High Growth Momentum
EPS Q2Q%3.94%
Sales Q2Q%8.33%
EPS 1Y (TTM)9.57%
Revenue 1Y (TTM)8.23%

BDX Forecast & Estimates

19 analysts have analysed BDX and the average price target is 209.55 USD. This implies a price increase of 9.24% is expected in the next year compared to the current price of 191.82.

For the next year, analysts expect an EPS growth of 3.94% and a revenue growth 4.3% for BDX


Analysts
Analysts72.63
Price Target209.55 (9.24%)
EPS Next Y3.94%
Revenue Next Year4.3%

BDX Ownership

Ownership
Inst Owners92.24%
Ins Owners0.57%
Short Float %1.09%
Short Ratio1.53